DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that Neoprobe and the University of California, San Diego (UCSD) have executed a definitive license agreement involving development rights to a molecular compound developed by researchers at UCSD. The new agreement accords Neoprobe the right to develop products using the compound for human medical applications incorporating optical or ultrasound technology. In addition, the development rights to the compound have been expanded to include veterinary applications. The compound is covered by U.S. patent 6,409,990 and corresponding issued patents in the European Union and Japan.
